Medical Affairs

CORKLIN R. STEINHART, M.D., Ph.D. M.S. F.A.C.P.

CURRICULUM VITAE

May 2019

ADDRESS ***** ********** ***** *****

Orlando, FL 32827

Mobile: +1-407-***-****

Email:*****.*********@*****.***

EDUCATION Post Graduate

Medical Residency in Internal Medicine

University of Miami - Jackson Memorial Hospital: Miami, FL June 24, 1986 - June 30, 1989

Medical

University of South Florida - College of Medicine: Tampa, FL 1982-1986

M.D., May 1986

Graduate

The Johns Hopkins University: Baltimore, MD

September 1976 - July 1980

Ph.D. in Cardiovascular Physiology, July 1981

Bucknell University

Lewisburg, PA September 1969 - August 1970

M.S. in Secondary Education, August 1970

Undergraduate

State University of New York at Buffalo: Buffalo, NY May 1974 - May 1976

Science Courses

Bucknell University: Lewisburg, PA

September 1965 - June 1969

B.S. in Secondary Education, June 1969

EMPLOYMENT Head, Global Medical Directors

ViiV Healthcare

Sept 2014-April 2019

Global Medical Lead: Triumeq and Executive Director, Medical Strategy North America ViiV Healthcare

June 10, 2013-Oct 2014

US Director Med Affairs HIV, HCV: Canadian Director Med Affairs HIV/HCV, and Global Point of Contact for HIV/HCV Co-infection

Global Medical Affairs, Merck

May 1, 2011-June 7, 2013

Senior Franchise Medical Director, Infectious Diseases Global Medical Affairs, Merck

February 2010-May 1, 2011

US Regional Director Medical Affairs, Virology

Merck Vaccines and Infectious Diseases

West Point, PA

January 2009-January 2010

Senior Medical Director

Medical Affairs and Policy, HIV

Merck Vaccines and Infectious Diseases

West Point, PA

January 1, 2008-January 2009

Senior Medical Director-RMD Program

External Medical & Scientific Affairs

Merck & Co., Inc.

Upper Gwynedd, PA

August 1, 2007-Decemeber 31, 2007

Senior Medical Director

Policy, Public Health, and Medical Affairs

Vaccine Division

Merck & Co.

West Point, PA

March 2006-July 2007

President, Steinhart Medical Associates

Miami, FL

1992-2006

Medical Director, Florida/Caribbean AIDS Education and Training Center Tampa, FL

July 1, 1999-December 31, 2003

Medical Director, QUEST Comprehensive Care Network, Inc Philadelphia, PA

August 1997-March 1998

Medical Director, Florida AIDS Education and Training Centers Network Miami, FL

July 1997-August 1998

Regional Medical Director, QUEST Comprehensive Care Philadelphia, PA

August 1996-July 1997

Medical Director, Special Immunology Services: Mercy Hospital Miami, FL

June 1, 1992 –March 1, 2000

Medical Director, Home Patient Care, Inc.

Ft. Lauderdale, FL

April 1994 - January 1995

Medical Director, Ablecare

Miami, FL

November 1991 - March 1994

Private Practice, Internal Medicine/HIV Disease

Miami, FL

1989 - 2006

Research Fellow, Suncoast Cardiovascular Research Laboratory University of South Florida College of Medicine

Tampa, FL

July 1980 - August 1982

Research Assistant, Department of Physiology

State University of New York at Buffalo

Buffalo, NY

September 1975 - May 1976

Coordinator, Cardiac Exercise Laboratory

Millard Fillmore Hospital

Buffalo, NY

April 1974 - August 1975

Mathematics Instructor and Athletic Coach

Ransom School

Miami, FL

September 1971 - February 1972

Mathematics Instructor and Athletic Coach

Kiski School

Saltsburg, PA

September 1970 - June 1971

POSITIONS/

COMMITTEES

Member, Board of Directors, ICAN June 2011-Sept 17, 2012 (ICAN merged with AHF) Member, HIV/AIDS Grants Advisory Committee, Merck, 2007-2008 Member, Board of Directors, AIDS Healthcare Foundation, 2005-2006 Chairman, Clinical Practice Committee, American Academy of HIV Medicine, 2004-2005 Scientific Advisory Board, URRMA Biopharma, 2001-2003 Chairperson: Mercy Hospital Institutional Review Board, 2001-2006 Chairperson: OWL Registry, BTG, Inc, 2001-2003

Member, Medical Care Subcommittee, Ryan White Title I, 1999-2000 Board of Directors, IDT, Inc., April 1999-2003

Ziagen® Physician Network, May 1999-Oct 1999

Co-Moderator, Medscape HIV Listserv, 10/98-6/00

Consultant, General Medical Industries, Inc., 1998-2000 Scientific Advisory Committee: IDT, Inc, 1994-2002 Board of Directors, Campbell Laboratories, Inc., 1994 - Medical Advisory Committee, Catholic Hospice, Inc., 1994 -1996 Senior Attending Physician, Mercy Hospital, Miami, FL, 1993 -2006 Attending Physician, Mercy Hospital, Miami, FL, 1989 - 1993 Board of Directors, Community Research Initiative of South Florida, 1992 - 1993 Medical Advisory Committee, Community Research Initiative of South Florida, 1989 -1995 AIDS Task Force Committee, Mercy Hospital, Miami, FL, 1991 - ; Co-Chairperson 1995 -2000 Board of Directors, CURE AIDS NOW, Miami, FL, 1991 - 1992 Medical Consultant, American Life Resources Corporation, Miami, FL, 1991 - 1992 Physician Consultant, Med-Trac, Inc., Minneapolis, MN, 1991 -2001 ACADEMIC

APPOINTMENTS

Consultant Faculty, Florida/Caribbean AETC, Jan 2004-2006 Assistant Professor of Medicine, Department of Medicine, University of South Florida College of Medicine, May 2001-Dec 2003

Assistant Clinical Professor, Department of Community Mental Health, University of South Florida, July 1, 1999-Dec 2003

Adjunct Assistant Professor of Family Medicine and Community Health, University of Miami, July 1, 1997-August 1, 1998

PROFESSIONAL

ORGANIZATIONS

Fellow, American College of Physicians

Past member American Academy of HIV Medicine

HIVMA of IDSA

Past Member International Association of Physician in AIDS Care International AIDS Society

Prior

CONSULTANT/

ADVISOR

GSK, Tibotec, Boehringer Ingelheim, Roche/Trimeris, Gilead, Council of Advisors, BMS, Merck Clinical Ad Board

RESEARCH

INVESTIGATIONS

Gilead Sciences, Inc., GS-US-183-0105: A Phase 2, Randomized Study of the Treatment of Antiretroviral Treatment-Experienced, HIV-1 Infected Subjects Comparing Ritonavir-Boosted Protease Inhibitor (CPI/r) in Combination with a Background Antiretroviral Therapy, 2006 Pfizer, Inc., A0081095: An Open-Label, Extension Safety and Efficacy Trial of Pregabalin in Subjects with Neuropathic Pain Associated with HIV Neuropathy, 2006 Incyte, INCB 08721-204: “A Randomized, Double-Blind, Phase II Study Comparing the Anti-Retroviral Safety and Efficacy of Dexelvucitabine (DFC) 200 mg Once Daily to Lamivudine (3TC) 300 mg Once Daily in Addition to Optimized Background Therapy in HIV-1 Infected Subjects Who Have Failed and/or Harbor HIV with Resistance Mutations to NRTIs, Pis, and NNRTIs”. 2005- Tibotec, TMC 125-C206: A Phase III Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Tolerability and Safety of TMC 125 as Part of an ART Including TMC 114/RTV and an Investigator-Selected OBR in HIV-1 Infected Subjects With Limited to no Treatment Options. 2005-

Tibotec, TMC 114-C226: Early Access of TMC 114 in Combination With Low Dose Ritonavir (RTV) and Other Antiretrovirals (ARVs) in Highly Treatment Experienced HIV-1 Infected Subjects With Limited to no Treatment Options. 2005-

VIRxSYS Corporation, Inc., VRX496-USA-05-002: A Phase II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, and Biological Activity of Repeated Doses of Autologous T Cells Transduced with VRX496 in HIV-Positive Subjects. 2005-

GlaxoSmithKline Sponsored: COL103952: Randomized Trial Comparing the Efficacy and Safety of RTV- Boosted Lexiva with Truvada Versus RTV-Boosted Reyataz with Truvada in Antiretroviral-Naïve Patients Over 48 Weeks 2005-

Pfizer, Pregabalin A0081066: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi- Center Trial of Pregabalin Versus Placebo in the Treatment of Neuropathic Pain Associated with HIV Neuropathy 2005-

Tibotec, TMC114-C209: “Open-Label Safety Study of TMC114 in Combination With Low Dose RTV and Other ARVs in Highly Experienced HIV-1 Infected Patients With Limited or no Treatment Options” 2005- Tibotec, TMC125-C229: An Open-Label Trial with TMC125 in HIV-1 Infected Subjects, Who Were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trial and Were Treated For at Least 48 Weeks 2005-2005.

Tibotec, TMC114-C214: A Randomized, Controlled, Open Label Trial to Compare the Efficacy and Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment Experienced HIV-1 Infected Patients 2005- Boehringer Ingelheim 1182.70” A Phase lllb, Open Label, Non Randomized Treatment Protocol of Tipranavir Co-Administered with Low Dose Ritonavir in Protease Inhibitor-Experienced Patients with HIV-1 Infection (Expanded Access Program) 2004-

Boehringer Ingelheim 1182.70” A Phase lllb, Open Label, Non Randomized Treatment Protocol of Tipranavir Co-Administered with Low Dose Ritonavir in Protease Inhibitor-Experienced Patients with HIV-1 Infection (Expanded Access Program) 2004-2005. Bristol-Myers Squibb: A Phase IV, Multicenter, Cross-Sectional Study to Evaluate 150L Substitution Among Subjects Experiencing Virologic Failure on a HAART Regimen Containing Atazanavir (ATV) 2004-

Serono Study 25373: A Phase III, Multicenter, Open-Label, 12 Week, Follow-up Safety and Efficacy Study of Serostim in Subjects with Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome (HARS)

Pfizer A4001029: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427, 857, in Combination with Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced, Non CCR5-Tropic HIV-1 Infected Subjects 2004-

Pfizer A4001027: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427, 857, in Combination with Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects 2004-

Pfizer A4001026: Multi-Center, Double Blind, Randomized, Double-Blind, Comparative Trial of a Novel CCR5 Antagonist, UK-427, 857, in Combination with Zidovudine/Lamivudine Versus Efavirenz in Combination with Zidovudine/Lamivudine for the Treatment of Antiretroviral-Naïve HIV-1 Infected Subjects 2004-

Gilead Sciences Protocol #GS-95-120: VistideTM (Cidofovir Intravenous) Treatment IND Protocol for Relapsing Cytomegalovirus in Patients with AIDS, 1995 -1997 Merck: CRIXIVANTM (Indinavir Sulfate) Program for People with Advanced HIV Disease, 1995 - 1996 Roche Laboratories: An Open-Label International Compassionate Treatment Program for the Use of Saquinavir (Ro 21-8959; HIV Protease Inhibitor) Either as Monotherapy or in Combination with Other Antiretroviral Drugs in Patients with Proven HIV Infection, 1995 -1996 Serono: An Open-Label, Multicenter Study to Provide Expanded Access to and to Obtain Additional Safety Data on SerostimTM (mammalian all-derived recombinant human growth hormone, r- hGH) in the Treatment of Adults with Advanced AIDS Wasting, Serono Protocol #7623, 1995 - 1997 US Bioscience: An Open-Label Phase IV Trial of Trimetrexate Therapy for Pneumocystis carinii Pneumonia (PCP) in Patients with AIDS to Evaluate the Effect of Adjunctive Corticosteroid Therapy: A Multicenter Trial Incorporating Secondary PCP Prophylaxis, 1994 Abbott Protocol M93-069: A Randomized Open-Label Study of Tolerability and Efficacy of Clarithromycin and Ethambutol in Combination with or without Clofazimime for the Treatment of DMAC in Patients with AIDS, 1994 -1995

Glaxo: 3TC Open-Label Program Protocol #NUCA3004, 1994 -1996 Syntex GANS2224: An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People with Limited Venous Access, 1994-1995 The Effect of Hyperbaric Oxygenation (HBO) on HIV-Associated Chronic Fatigue and Severe Periphera l Neuropathy, A Pilot Project, Mercy Hospital, Miami, FL, 1994 - 1995 A Preliminary Study of Hydroxychloroquine in HIV Infection, Collaborative Study with UCLA, 1992 – 1993

Bristol-Myers Squibb: d4T (Stavudine) Parallel Track Protocol, 1993 - 1994 RESEARCH

GRANTS

Unrestricted educational grant, Vertex, 2000

Unrestricted educational grant, Merck, 2000

Unrestricted educational grant, Serono, 2000

“Intraperitoneal Dextrin Sulfate in Patients with Advanced HIV Disease: A Phase I Trial,” GMI, Inc., 1999

Unrestricted educational grant, Ortho-Biotech, 1997 The Effect of Folinic Acid on the Hematological Toxicity of Selected Medications Used in the Treatment of Chronic HIV Infection: The Campbell Foundation, 1997. Unrestricted educational grant, Agouron, 1997

Unrestricted educational grant, Merck and Co., 1997 Unrestricted educational grant, Abbott Laboratories, 1996 Retrospective Analysis of Stavudine-Containing Combination Therapies: Bristol-Myers Squibb, 1995 – 1996

Bernard Hoffman Foundation, Millard Fillmore Hospital: 1974 Impact Study: Home Nutritional Services, Inc., 1991 Research Fellowship Recipient, American Heart Association, Suncoast Chapter: July 1981 - June 1982 N.I.H. Research Fellowship Recipient, Coronary Physiology: July 1980 - June 1981 Public Health Service Award, Physiology, The Johns Hopkins University School of Hygiene and Public Health: September 1976 - July 1980

National Advisory Committee on HIV Prophylaxis, 1990 BIBLIOGRAPHY Anita Chawla . Christina Wang . Cody Patton . Miranda Murray,Yogesh Punekar,Annemiek de Ruiter and Corklin Steinhart. A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population. Infect Dis Ther. https://doi.org/10.1007/ s40121-018-0201-6. Published online: 14 May, 2018

Steinhart, CR. Role of the pharmaceutical industry: the research strategy focused on HIV. Chapter 5. In: HIV/AIDS: History, care, prevention. Milano, It. 2016. Gavin A Cloherty, Thomas P Young, Danijela Lucic, Corklin Steinhart, Scott Letendre. Dried Blood Spots

(DBS) for Hepatitis C (HCV) Molecular Diagnostic Testing. J Hepat Res. Volume 1 Issue 4: 2014.

Gavin Cloherty, Neil Parkin, James Rhoads, Claudia Esping, n Steinhart, George Schneider, Lily Yuen and John Hackett, Jr. Sequence Conservation of the Region Targeted by the Abbott RealTi me HCV Viral Load Assay. J. Clin. Microbiol. 2014, 52(4):1220.

Gathe J, Cooper DA, Farthing C, Jayaweera D, Norris D, Pierone G, Steinhart CR, Trottier B, Walmsley SL, Workman C, Mukwaya G, Kohlbrenner V, Dohnanyi C, McCallister S and Mayers D for the RESIST-1 Study Group. Efficacy of the proteae inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24 week analysis from the RESIST-1 Trial. CID 2006; 43: 1337-46. Orrick JJ and CR Steinhart. Atazanavir. Ann Pharmacother. 2004; 38: 1664-74. Benson CA, Van Der Horst C, LaMarca A, Haas D, McDonald CK, Steinhart CR, Rublein J, Quinn JB, Mondou E, Rousseau F and the FTC-303/350 Writing Group. A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. AIDS 2004, 18: 2269-2276. Steinhart CR. Recent advances in the treatment of HIV/AIDS. Expert Rev Anti-Infect Therapy. 2004; 2(2): 197-211.

Steinhart CR and MF Emmons. Risks of Cardiovascular Disease with Antiretroviral Therapy. AIDS Reader. 2004; 14: 86-95.

Polsky B, Kotler, Steinhart C. Treatment guidelines for HIV-associated wasting. 2003; HIV Clin Trials. 5(1): 50-61.

Steinhart CR. Management of the Patient with HIV Infection or AIDS. Infections in Medicine. 2003; 20(11): 536-543.

Squires K, A Pozniak, G Pierone, C Steinhart, D Berger et al. Tenofovir disoproxil fumarate in nucleoside- resistant HIV-1 Infection. A randomized trial. Ann Intern Med. 2003; 139: 313-320. Steinhart, CR, JJ Orrick, K Simpson (Eds). HIV/AIDS Primary Care Guide. Gainesville: University of Florida, 2002.

CR Steinhart. HIV-associated wasting in the Era of HAART: A practice-based approach to diagnosis and treatment. AIDS Reader. 2001; 11 (11): 557-60, 566-69. Polsky B, Kotler D, and CR Steinhart. HIV-associated wasting in the HAART Era: guidelines for assessment, diagnosis, and treatment. AIDS Patient Care and STDs.2001; 15 (8): 411-423. Abrams DI, CR Steinhart, and R Frascino. Epoetin alfa therapy for anaemia in HIV-infected patients: impact on quality of life. Int’l J of STD and AIDS. 2000; 11: 659-665.

“HIV Treatment and Education for Infection. Curreent Status of The US and Japan. An interview with Corklin Steinhart, Medical Director, Florida Caribbean AIDS Education and Training Ceneter.”JAMA

(Japanese Version). 10 October 2000: 111-113.

Steinhart CR. Pathogenesis of HIV infection and implications for clinical practice. Clinical Immunology Newsletter 1999; 19 (12): 122, 126-131.

Steinhart, CR. HIV/AIDS Update ’99. Vital Signs 1999; .IX (2): 6. Steinhart CR. HIV Update 1998: Good news. Vital Signs. 1998: VII (14): 8. Steinhart CR. How to choose an HIV provider. Lifetimes 2 1998; 7(1): 4-5. Ash, SR, CR Steinhart, MF Curfman et al. Extracorporeal whole body hyperthermia treatments for HIV infection and AIDS. ASAIO J 1997; 43(5): M830-M838. Steinhart, CR. Choosing the right “cocktail” for patients with HIV/AIDS: not an easy task. Home Steinhart, CR, HIV/AIDS Update: The Second Decade: Implications for Mercy Hospital. Mercy Medicine IV (1) 4-7, 1993.

Yatvin, M.B., M.H.B. Stowell, and C.R. Steinhart. “Is There a Role for Hyperthermia in the Treatment of HIV Infection?” AIDS Patient Care. 7(1):5-9, 1993. ”Shedding Light on the Use of Heat to Treat HIV Infections.” Oncology. 50:380-389, 1993. “Hyperthermie Therapeutique et Infections a HIV: Mythe ou Realite?” Lyon Chir. 89:271-277, 1993.

Steinhart, C.R., S. Permutt, G.H. Gurtner and R.J. Traystman. “B-Adrenergic Activity and Cardiovascular Response to Severe Respiratory Acidosis.” American Journal of Physiology. 224:H 46-54, 1983.

Olsson, R.A., D. Saito, C.R. Steinhart. “Compartmentalization of the Adenosine Pool of Dog and Rat Hearts.” Circ. Res. 50:617-626, 1982.

Olsson, R.A., D. Saito, C.R. Steinhart. “Metabolic Regulation of Coronary Circulation.” The Physiologist. 25:51-55, 1982

Saito, D., C.R. Steinhart, D.G. Nixon and R.A. Olsson. “Intracoronary Adenosine Deaminase Reduces Canine Myocardial Reactive Hyperemia. Circ. Res. 49:1262-1267, 1981. Steinhart, C.R. “Diagnosis in the Exercise Laboratory.” CVP. March/April: 31-34, 1976. ABSTRACTS

Leen C, Shaunak S, Steinhart C, et al. Tolerability of a novel approach to salvage therapy for AIDS. 5th International Congress on Drug Therapy in HIV Infection. Glasgow, 2000. Steinhart CR. Pathogenesis of HIV Infection. 51st A.A.C.C. New Orleans, 1999. Galea P, C Steinhart, P Willem et al. Identification of a new virus-associated epitope inducing antibody responsible for the non progression to AIDS. 12th World AIDS Conference. Geneva, 1998. Berger D, G Bucher, P Cimoch, P Nemenchek, W Owen, and C Steinhart. Measurement of body weight and body cell mass in patients receiving highly active antiretroviral therapy (HAART). I.C.A.A.C. Toronto, 1997. Steinhart CR, SA George, and RD Mann. Salvage Therapy using the combination of ritonavir and saquinivir in patients with advanced HIV infection. 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC, 1997.

Steinhart CR, DA Jacobsen, SA George, and RD Mann. Open-label trial of stavudine and lamivudine in antiretroviral-naïve HIV-infected persons. New Insights in HIV Infection and Disease. Hilton Head, 1996. Steinhart, CR, DA Jacobsen, SA George, and RD Mann. Combination antiretroviral therapy with stavudine (d4T) and lamivudine (3TC): a retrospective analysis. Xith International Conference on AIDS. Vancouver, 1996. Steinhart CR, DA Jacobsen, and SA George. Retrospective Analysis of Combination Antiretroviral Therapy with Stavudine (d4T) and Hydroxyurea. 3rd Conference on Retroviruses and Opportunistic Infections. Washington, 1996.

Ash SR, CR Steinhart, MF Curfman, CH Gingrich, DA Sapir, CT Bick, and MB Yatvin. Extracorporeal Whole Body Hyperthermia for HIV Infection and AIDS. 3rd Conference on Retroviruses and Opportunistic Infections. Washington, 1996.

Steinhart, C.R., I. Montoya, and M.R. Kaiser. The Effect of Hyperbaric Oxygenation (HBO) on HIV-Associated Chronic Fatigue. Xth International Conference on AIDS. Yokohama, 1994. Hitchen, K.M. and C.R. Steinhart. Development of Guidelines for the Evaluation and Treatment of HIV/AIDS Patients in a Dedicated Unit of a Private Community Hospital. 28th Annual ASHP Midyear Clinical Meeting. Atlanta, 1993.

Steinhart, C.R. Hyperthermia and the HIV Patient: The View of a Front-Line Physician. 8th Annual Meeting of the American Society of Clinical and Hypertermic Oncology. Lincolnshire, IL, November 2, 1991. Steinhart, C.R., D.G. Nixon, and K.O. Zwolak. Effect of Theophylline and Adenosine Daminase on Coronary Vasoactivity of Acetate. Fed. Proc., 1982.

Steinhart, C.R., D.G. Nixon. Role of Acidosis in Myocardial Reactive Hyperemia. Fed. Proc., 1981. Steinhart, C.R., S. Permutt, G.H. Gurtner, and R.J. Traystman. Effects of Sodium Bicarbonate and Calcium on the Cardiovascular Response to Severe Respiratory Acidosis. Physiologist. 22:119, 1979. Invited Lectures

Hong Kong College of Family Physicians, Hong Kong, January 2019 ART-Mediated Mental Health Side Effects, NIH National Insitutute of Mental Health, Bethesda, MD, September 2018

15th Annual AIDS Workshop, Riyadh Saudi Arabia, December 2018 VI Eastern European and Central Asian AIDS Conference, Moscow April 2018 Hong Kong Infectious Disease Society Annual Meeting, Hong Kong, June 2017 6th Asian Conference on Hepatitis and AIDS, Shenzhen, China, May 2017 5th Asian Conference on Hepatitis and AIDS, Nanjing, China, May 2016 Turkish National HIV Congress, Ankara, November 2015

“Interpretation of Resistance Reports-What Do the Data Mean in Clinical Practice.” Strategic Directions in HIV Therapy. Rhodes, Greece, March 12-13, 2004

“HIV-Associated Wasting in the Era of HAART: Tokyo University Medical College, Nagoya National Hospital, Hiroshima University Medical School, August 2000

“HIV Update 1998: Nagoya National Hospital; Fukuyama National Hospital; Hiroshima University School of Medicine; Mitoyu National Hospital, April 1998

“AIDS Frontier: Current Progress and Clinical Update.” Okayama University Medical School, August 5, 1994. AWARDS AND SPECIAL ACIEVEMENTS

Special Achievement Award for BOC NPP: March 2011

Award of Excellence, Isentress Marketing Team, April 2010 Special Achievement Award for Isentress: Marketing and Leadership Principles Recognized, Oct 2009 Special Achievement Award for Isentress: : Marketing and Leadership Principles Recognized, Sept 2009 Finalist: Brand of Year, Best Marketing Event Management, June 2009 Special Achievement Award for Isentress, Dec 2008

Awards for Excellence 2008: April, May, December

2007 Merck GHH Marketing Award: MVID Franchise of the Year Finalist Special Recognition Award, Isentress, Managed Care Division, Merck & Co, December 2007 Special Recognition Award, Isentress, Marketing Division, Merck & Co, November 2007 MVD Values Award, Merck Vaccine Division, May 2007 Mercy Hospital Recognition Award, Mercy Hospital Staff and Administration, June 2006 Florida/Caribbean AIDS Education and Training Center Recognition Award, March 2004 Special Recognition Award, Mercy Hospital, 2001

HIV Resistance Testing Educational Seminars "Stay the Course" Award, Dec 2003

“Twelve Good Men”. Ronald McDonald House, Miami, FL, February 1995. Certificate of Appreciation. Knights of Columbus, Miami, FL, December 1994. Certificate of Appreciation. PWAC of Dade County, Miami, FL, September 1994. CERTIFICATIONS

State of Florida Medical License: ME 51905

Commonwealth of Pennsylvania Medical License: MD433751 Diplomate, American Board of Internal Medicine, September 25, 1991. Recertified 2002 - 2012

HIV Specialist, American Academy of HIV Medicine, 2002-2003 Recertified 2004-2005, 2009-2011

Contact this candidate